ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · EFO_0000180

HIV-1 infection

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. HIV-1 infection. Diseases, record EFO_0000180. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0000180

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
HIV-1 infection
Open Targets
Open Targets ID
EFO_0000180
Open Targets
Other names
HIV-1 seropositive, Human Immunodeficiency Virus 1, Human Immunodeficiency Virus, Type 1
Open Targets
NCI Thesaurus
C14220
NCI Thesaurus
Highest stage of its drugs
Approval, for 35 of its 73 drugs, from ClinicalTrials.gov, DailyMed, FDA and PMDA
Open Targets

Drugs73

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
RITONAVIRCHEMBL163Small moleculeApprovalClinicalTrials.gov and DailyMed242020Drugs and targets
LAMIVUDINECHEMBL141Small moleculeApprovalDailyMed and FDA211110Drugs and targets
LOPINAVIRCHEMBL729Small moleculeApprovalDailyMed1199Drugs and targets
ZIDOVUDINECHEMBL129Small moleculeApprovalDailyMed1287Drugs and targets
EMTRICITABINECHEMBL885Small moleculeApprovalDailyMed, FDA and PMDA3077Drugs and targets
EMTRICITABINE, (+/-)-CHEMBL161381Small moleculeApprovalPMDA1577Drugs and targets
MARAVIROCCHEMBL256907Small moleculeApprovalPMDA766Drugs and targets
TENOFOVIR DISOPROXIL FUMARATECHEMBL1486Small moleculeApprovalDailyMed and PMDA2255Drugs and targets
NEVIRAPINECHEMBL57Small moleculeApprovalDailyMed655Drugs and targets
RILPIVIRINECHEMBL175691Small moleculeApprovalDailyMed, FDA and PMDA844Drugs and targets

1 to 10 of 73

See all 73 drugs

Targets30

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
CD274Programmed cell death 1 ligand 12Programmed cell death 1 ligand 1 binding agent; Programmed cell death 1 ligand 1 inhibitorPhase 2https://conductscience.org/library/genes/29126Drugs and targets
CYP3A4Cytochrome P450 3A2Cytochrome P450 3A inhibitorApprovalhttps://conductscience.org/library/genes/1576Drugs and targets
CYP3A43Cytochrome P450 3A2Cytochrome P450 3A inhibitorApprovalhttps://conductscience.org/library/genes/64816Drugs and targets
CYP3A5Cytochrome P450 3A2Cytochrome P450 3A inhibitorApprovalhttps://conductscience.org/library/genes/1577Drugs and targets
CYP3A7Cytochrome P450 3A2Cytochrome P450 3A inhibitorApprovalhttps://conductscience.org/library/genes/1551Drugs and targets
CCR5C-C chemokine receptor type 51C-C chemokine receptor type 5 antagonistApprovalhttps://conductscience.org/library/genes/1234Drugs and targets
CD4T-cell surface glycoprotein CD41T-cell surface antigen CD4 inhibitorApprovalhttps://conductscience.org/library/genes/920Drugs and targets
CSF2RAGranulocyte-macrophage colony-stimulating factor receptor1Granulocyte-macrophage colony-stimulating factor receptor agonistUnknownhttps://conductscience.org/library/genes/1438Drugs and targets
CSF2RBGranulocyte-macrophage colony-stimulating factor receptor1Granulocyte-macrophage colony-stimulating factor receptor agonistUnknownhttps://conductscience.org/library/genes/1439Drugs and targets
CSF3RGranulocyte colony-stimulating factor receptor1Granulocyte colony stimulating factor receptor agonistUnknownhttps://conductscience.org/library/genes/1441Drugs and targets

1 to 10 of 30

See all 30 targets

Trials70

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT00665561Prospective Observational Epidemiologic Study of Maraviroc's Safety2,5002020-04-07Human Immunodeficiency VirusMARAVIROCIts record names the diseaseClinicalTrials.gov
NCT02269917
Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants
Phase 31,1492018-11-09Human Immunodeficiency Virus Type 1COBICISTAT, DARUNAVIR, EMTRICITABINE, EMTRICITABINE, (+/-)-, TENOFOVIR ALAFENAMIDEIts record names the diseaseClinicalTrials.gov
NCT02831764An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)Phase 37222019-04-22Infection, Human Immunodeficiency Virus, HIV InfectionsDOLUTEGRAVIR, LAMIVUDINEIts record names the diseaseClinicalTrials.gov
NCT02607956
Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Phase 36572018-06-06HIV-1 InfectionBICTEGRAVIR, EMTRICITABINE, EMTRICITABINE, (+/-)-, TENOFOVIR ALAFENAMIDEIts record names the diseaseClinicalTrials.gov
NCT03048422Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their InfantsPhase 36432021-11-10HIV InfectionsDOLUTEGRAVIR, EFAVIRENZ, EMTRICITABINE, EMTRICITABINE, (+/-)-, TENOFOVIR ALAFENAMIDE, TENOFOVIR DISOPROXIL FUMARATEIts record names the diseaseClinicalTrials.gov
NCT00524368A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)Phase 35902010-09-22Human Immunodeficiency Virus - Type 1DARUNAVIR, RITONAVIRIts record names the diseaseClinicalTrials.gov
NCT04399551A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European CountriesPhase 34372023-05-19HIV InfectionsCABOTEGRAVIR, RILPIVIRINEIts record names the diseaseClinicalTrials.gov
NCT02120352
A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects
Phase 23092020-08-31Infection, Human Immunodeficiency Virus, HIV InfectionsCABOTEGRAVIR, RILPIVIRINEIts record names the diseaseClinicalTrials.gov
NCT01083810Evaluation of Kaletra Therapy Over the Long-term2842011-07-29Human Immunodeficiency VirusLOPINAVIR, RITONAVIRIts record names the diseaseClinicalTrials.gov
NCT01384734HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) InfectionsPhase 22542018-11-14Infection, Human Immunodeficiency VirusFOSTEMSAVIR, RALTEGRAVIR, TENOFOVIR DISOPROXIL FUMARATEIts record names the diseaseClinicalTrials.gov

1 to 10 of 70

See all 70 trials

Comparisons in its trials24

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
Maraviroc Exposed vs Maraviroc Unexposed: deaths from any cause75 of 1,31679 of 1,1302,446NCT00665561Trial comparisons
Maraviroc Exposed vs Maraviroc Unexposed: serious adverse events435 of 1,316352 of 1,1302,446NCT00665561Trial comparisons
DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase: Number of Participants Who Discontinue Treatment Due to AEs Over Week 14413 of 36016 of 359719NCT02831764Trial comparisons
DRV/Rtv 800/100 mg Once Daily vs DRV/Rtv 600/100 mg Twice Daily: Virological Response at Week 48 (Number of Participants With Plasma Viral Load Less Than 50 Copies/mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
212 of 294210 of 296590NCT00524368Trial comparisons
DRV/Rtv 800/100 mg Once Daily vs DRV/Rtv 600/100 mg Twice Daily: Virologic Response at Week 48 (Viral Load Less Than 400 Copies/mL)226 of 294227 of 296590NCT00524368Trial comparisons
DRV/Rtv 800/100 mg Once Daily vs DRV/Rtv 600/100 mg Twice Daily: serious adverse events16 of 29427 of 296590NCT00524368Trial comparisons
FTR/RAL/TDF Total vs ATV/r/RAL/TDF: deaths from any cause3 of 2000 of 51251NCT01384734Trial comparisons
FTR/RAL/TDF Total vs ATV/r/RAL/TDF: serious adverse events35 of 2008 of 51251NCT01384734Trial comparisons
E/C/F/TAF + LDV/SOF vs F/R/TAF + LDV/SOF: deaths from any cause0 of 741 of 74148NCT02707601Trial comparisons
E/C/F/TAF + LDV/SOF vs F/R/TAF + LDV/SOF: serious adverse events7 of 7412 of 74148NCT02707601Trial comparisons

1 to 10 of 24

See all 24 comparisons in its trials

Papers from its trials49

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
33880558RESULT1PubMed
33812487RESULT1PubMed
32504574RESULT1PubMed
31068272RESULT1PubMed
31068270RESULT1PubMed
30932951RESULT1PubMed
30803969RESULT1PubMed
29956087RESULT1PubMed
28867499RESULT1PubMed
28166190RESULT1PubMed

1 to 10 of 49

See all 49 papers from its trials

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0000180

GET https://conductscience.org/api/diseases/v1/EFO_0000180/drugs?page=2

API referenceFor AI assistants